Active Not RecruitingNCT06480500
i-CBT and IV Ketamine for Suicide prevention in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Medication studyAges 21–65Canada
Understand this study
Who could participate?
Listed age limits: 21 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 2, 2024
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 76
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT06480500
- Official title
Show the full official title
Integrated Internet-Based Cognitive Behavioural Therapy (i-CBT) and Intravenous Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Questions about this study
Who is behind this study?
The study sponsor is University Health Network, Toronto, a university.
Does this study involve medication?
Yes. The study involves medication, including Ketamine hydrochloride and Midazolam Hydrochloride.
Who can participate?
Listed age limits: 21 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
